Literature DB >> 20216308

Postresuscitation care: entering a new era.

Jerry P Nolan1, Jasmeet Soar.   

Abstract

PURPOSE OF REVIEW: The purpose of this study is to discuss recent data relating to the treatment of cardiac arrest survivors. This is a rapidly evolving component of resuscitation medicine that impacts significantly on the quality of survival after cardiac arrest. RECENT
FINDINGS: The postcardiac arrest syndrome comprises postcardiac arrest brain injury, postcardiac arrest myocardial dysfunction, the systemic ischaemia/reperfusion response, and the persistent precipitating disease. Primary percutaneous coronary intervention is the preferred method for restoring coronary perfusion when cardiac arrest has been caused by an ST-elevation myocardial infarction. Many cardiac arrest survivors with non-ST-elevation myocardial infarction may also benefit from urgent percutaneous coronary intervention. Comatose cardiac arrest survivors should be managed with a moderate blood glucose target range of below 10 mmol/l (180 mg/dl). Therapeutic hypothermia is now generally accepted as part of a treatment strategy for comatose survivors of cardiac arrest, but its use may render conventional methods of prognostication unreliable.
SUMMARY: Survivors from cardiac arrest develop a postcardiac arrest syndrome. Postresuscitation care, including primary percutaneous coronary intervention, therapeutic hypothermia, and control of blood sugar, improves survival and neurological outcome in cardiac arrest survivors. Completely reliable prognostication in comatose survivors of cardiac arrest is difficult to achieve.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20216308     DOI: 10.1097/MCC.0b013e3283383dca

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  8 in total

1.  Prognosis after cardiac arrest and hypothermia: a new paradigm.

Authors:  Edgar A Samaniego; Suzanne Persoon; Christine A C Wijman
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

2.  Awakening and withdrawal of life-sustaining treatment in cardiac arrest survivors treated with therapeutic hypothermia*.

Authors:  Maximilian Mulder; Haley G Gibbs; Stephen W Smith; Ramnik Dhaliwal; Nathaniel L Scott; Mark D Sprenkle; Romergryko G Geocadin
Journal:  Crit Care Med       Date:  2014-12       Impact factor: 7.598

3.  Combining NSE and S100B with clinical examination findings to predict survival after resuscitation from cardiac arrest.

Authors:  Luis M Calderon; Francis X Guyette; Ankur A Doshi; Clifton W Callaway; Jon C Rittenberger
Journal:  Resuscitation       Date:  2014-04-30       Impact factor: 5.262

4.  Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German-Austrian S3 Guideline.

Authors:  Karl Werdan; Martin Ruß; Michael Buerke; Georg Delle-Karth; Alexander Geppert; Friedrich A Schöndube
Journal:  Dtsch Arztebl Int       Date:  2012-05-11       Impact factor: 5.594

5.  Evidence-based Management of Cardiogenic Shock After Acute Myocardial Infarction.

Authors:  Karl Werdan; Martin Russ; Michael Buerke; Roland Prondzinsky; Sebastian Dietz
Journal:  Interv Cardiol       Date:  2013-08

6.  Is Procalcitonin a Marker of Neurologic Outcome or Early Infection in Patients Treated with Targeted Temperature Management?

Authors:  Ciler Zincircioglu; Tunzala Yavuz; Aykut Sarıtaş; Meltem Çakmak; Işıl Köse Güldoğan; Uğur Uzun; Nimet Şenoğlu
Journal:  Indian J Crit Care Med       Date:  2020-05

7.  Three-Dimensional Shapes and Cell Deformability of Rat Red Blood Cells during and after Asphyxial Cardiac Arrest.

Authors:  Hui Jai Lee; SangYun Lee; HyunJoo Park; YongKeun Park; Jonghwan Shin
Journal:  Emerg Med Int       Date:  2019-10-15       Impact factor: 1.112

8.  Therapeutic Hypothermia Protects Against Heat Stroke-Induced Arterial Hypotension via Promoting Left Ventricular Performance in Rats.

Authors:  Wen-Ching Ko; Cheng-Hsien Lin; Jie-Jen Lee; Ching-Ping Chang; Chien-Ming Chao
Journal:  Int J Med Sci       Date:  2020-02-10       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.